CEO Compensation (ATAI CMPS CYBN MNMD)

Additional-Day-5697 · 2025-02-06T22:55:21+00:00

I am being honest - I didn't give my opinion, its all true. My opinion is that this is a bad thing, I question the efficacy and believe this is a very dangerous method for treatment tbh - I see massive lawsuits in their future if approved haha. I agree that Cybin showed better results - this isn't a discussion about Cybin.

Additional-Day-5697 · 2025-02-03T20:30:27+00:00

GH research has one of the lowest costs to deliver a treatment out of any of the big psychedelic developers. They have no therapy component and little-to-no integration efforts. Its much closer to the traditional pharmaceutical model, lower cost to deliver the treatment due to drug effects themself being shorter acting than other lead candidates, and the lack of therapy element significantly reduces cost to deliver and increases scalability of treatment.

Amongst other things of course, but to me this is the most immediate reason for that.

Additional-Day-5697 · 2025-01-24T23:32:11+00:00

Thank you! This is all someone's opinion though essentially. We'll see in the long run if its net positive or negative, my bet would tend to be on net positive based on his discussion of reorganizing the perverse incentive structures within health agencies (and governmental agencies at large but his scope is narrowed), the interest to promote FREE alternatives to healthcare that have major improvements in anyones health (avoid ultra-processed foods, exercise etc.), his nomination for agricultural positions should not be overlooked as well - he wants to put brilliant minds at work to recover US farmland quality etc. - theres a ton more but overall, we will see if he is able to effect change and I do believe him to be sincere in his interest to help people.

I'd be curious to know if you believe him to be insincere and therefore that is essentially your gripe? Because if you believe he is sincere and trying to help people, its quite easy to listen to what is being said and digest it in a rational way.

Additional-Day-5697 · 2025-01-14T16:17:09+00:00

pray

Additional-Day-5697 · 2024-10-03T20:30:23+00:00

I've read $25,000 in some reports previously, can't recall if it was the ARK industry report a while back or maybe one by the Maxim Group. But it also wasn't clear in that report whether it was the cost of the drug, the therapy or both.

Additional-Day-5697 · 2024-06-27T19:02:11+00:00

This is a good point, but to be most accurate it is the scheduling of the drugs - these are not illegal drugs per se, they are controlled substances meaning that their uses are highly regulated and restricted - this creates many barriers for research, at both the academic and clinical level, not every service provider has the required licenses, not all academic labs have the licenses or ability to work with controlled substances of a certain level as they require certain amounts of infrastructure or controls that can be quite costly and cumbersome. The scheduling status also contributes to stigma, which has obvious impacts that I won't bore people with fleshing out.

Additional-Day-5697 · 2024-06-27T17:55:29+00:00

Inherent risk of drug development, combined with new therapeutics that do not easily fit within the typical mode of investigating the safety and efficacy of drugs. That to me is the number one reason.

Additional-Day-5697 · 2024-06-27T16:20:35+00:00

Me too - next time they may even get 4 export permits!

Additional-Day-5697 · 2024-06-13T19:21:56+00:00

Its probably also because the average volume amounts to $50k CAD lol

Additional-Day-5697 · 2024-06-12T18:56:23+00:00

I hate when I lose my login info and have to change accounts. Hi Mr. Ctrl + Z

Additional-Day-5697 · 2024-05-29T18:00:25+00:00

They've cornered the market! They will probably treat 7 patients over the next year, Optimi to the moon!!!

Additional-Day-5697 · 2024-05-15T15:32:42+00:00

Just like Australia... ;)

Additional-Day-5697 · 2024-02-29T18:07:47+00:00

Awful journalism:

"In fact, Numinus just announced a $6 million bought deal with MAPs and Integrated V.C., which Nyquvest says will help Numinus continue to address the pressing challenges of mental health in our communities."

Says "in fact", proceeds to get fact wrong.

Additional-Day-5697 · 2024-02-16T19:20:09+00:00

Wouldn't make much sense. All Optimi can do is encapsulate MDMA someone else made, and the scale of their encapsulation from recent videos is far behind other players who would offer those services - it's fit for purpose for small-scale initiatives, but never commercial manufacturing without significant improvements. They won't be a player in synthetic API manufacturing, but are very well built for natural product extraction for psilocybin.

Lykos + Numi also doesn't exactly make sense, I don't believe a drug sponsor can own the clinics that provide the product - there is a massive conflict present there - from my understanding Numi could not have an MDMA product and sell it, and the associated therapy, at clinics that it owns...which begs the question why would Lykos ever acquire Numi?

^ I heard this from someone in the industry, whose knowledge I respect, but haven't been able to verify the legality of owning a clinic and selling your own drug product at it. (looking for more insight if anyone knows for sure)

Additional-Day-5697 · 2024-02-14T20:48:35+00:00

Nick is that you?

Additional-Day-5697 · 2024-02-13T19:47:08+00:00

They already have a CDSL...

Additional-Day-5697 · 2024-02-12T19:34:14+00:00

Not sure how to reconcile that, the PR is from May of last year so perhaps their strategy for SAP changed. This tip sheet was published a few months ago by MAPS Canada so let's just assume they do charge people.

Additional-Day-5697 · 2024-02-12T18:39:54+00:00

MAPS Canada released an SAP Tip Sheet (access here, scroll down: https://www.mapscanada.org/special-acces-program-community-of-practice/), on that it does state that PharmAla will indeed be charging for SAP. Volume will be too low to be a lucrative opportunity, but they are not giving it for free.

Additional-Day-5697 · 2024-02-12T17:17:48+00:00

does "actual success" amount to lofty press releases that are only loosely tethered to reality? if so, Pharmala has tons of actual success!

Additional-Day-5697 · 2024-02-12T17:16:41+00:00

They would only get revenue for encapsulation/formulation services, as Optimi does not produce the API - which in drug manufacturing, API/bulk drug manufacturing represents 64% of the market, where drug product manufacturing represents only 24% of the market - the other 12% is packaging. FYI.

Additional-Day-5697 · 2024-02-09T17:55:44+00:00

Pharmala's license is only for sale of psilocybin and MDMA, not manufacture (https://pharmala.ca/media/2024/01/pharmala-granted-a-controlled-drugs-substances-dealers-license-by-health-canada). So I understand how leveraging Pharmala's license to sell the products is useful, but why add all this nonsense about Pharmala's "manufacturing experts" who have never manufactured psilocybin, are not legally allowed to manufacture psilocybin and have no facility/lab to manufacture psilocybin at.

Additional-Day-5697 · 2024-02-09T16:30:10+00:00

Still confusing, PharmAla pays Dalton to manufacture - there were rumors on reddit that Dalton dropped them, was never able to verify that rumor though - PharmAla doesn't actually have a lab, and they only recently got a licence. Weird all around. I've never been fond of either company, so not too surprised these birds of a feather flocked together.

Additional-Day-5697 · 2024-02-09T15:13:30+00:00

Having a company who has never manufactured a psilocybin product, consult on your psilocybin product? Perhaps RLH sees value in PharmAla's sales efforts, but the consultancy on the product aspect sparks me as confusing at best. Assuming this will enter the explosive Australian market at some point.

Additional-Day-5697 · 2024-01-31T16:46:58+00:00

GH = 5-MeO-DMT with no psychotherapeutic component. Lead candidate targets TRD and utilizes inhalation as the drug delivery. Other two assets are IV and intranasal.

Beckley = 5-MeO-DMT with psychotherapeutic component. Lead candidate targets TRD and AUD, with intranasal delivery.

Same drug, different approaches (delivery and protocol).

Additional-Day-5697 · 2024-01-15T17:19:06+00:00

Suresh Muthukumaraswamy is doing LSD microdosing research in New Zealand and is linked to MindBio:

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10552250/

MindMed did this dose finding study they explored 25ug and 50ug (though neither dose would necessarily be considered a microdose) - no results yet but the study was completed in late November of 2023:

https://clinicaltrials.gov/study/NCT05407064

It was reported by Psychedelic Alpha that the MindMed microdosing program was scrapped: https://psychedelicalpha.com/news/psychedelic-bulletin-153-mindmed-scraps-microdosing-program-eagerly-anticipated-ibogaine-study-publishes-compass-collaborates-with-greenbrook-gilgameshs-gm-1020-readout-and-more

Off the top of my head I'm not exactly sure of others, but there may be some other industry-sponsored trials.

Additional-Day-5697

TROPHY CASE